Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 2/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 4/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 4/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | XIAP | P98170 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28308562 | 1.00 | DPP4 (0.38) | DPP4SLC15A1PAX8TERTCARM1 | |
| SCHEMBL9343726 | 0.84 | CYP2D6 (0.34) | DPP4 | |
| SCHEMBL14442120 | 0.84 | DPP4 (0.39) | DPP4SLC15A1PAX8TERTCARM1 | |
| SCHEMBL13209257 | 0.84 | DPP4 (0.39) | DPP4SLC15A1PAX8TERTCARM1 | |
| SCHEMBL19882810 | 0.83 | PIK3CD (0.39) | DPP4SLC15A1PAX8TERTCARM1 | |
| SCHEMBL29645831 | 0.83 | PIK3CD (0.39) | DPP4SLC15A1PAX8TERTCARM1 | |
| SCHEMBL23341077 | 0.81 | DPP4 (0.36) | DPP4SLC15A1PAX8TERTCARM1 | |
| SCHEMBL25118870 | 0.80 | DPP4 (0.33) | DPP4SLC15A1TERTCARM1PRMT6 | |
| SCHEMBL23173377 | 0.79 | KDM4E (0.38) | DPP4SLC15A1PAX8TERTCARM1 | |
| SCHEMBL2580662 | 0.78 | CTSS (0.40) | DPP4SLC15A1PAX8TERTCARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
| CN-110066302-A | Glucopyranosyl derivatives and application thereof | 广东东阳光药业有限公司 | 2019-07-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | DPP4 4337/4885SLC15A1 3391/4885PAX8 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.